Brazil Health Ministry restricts insulin tender to registered firms; Global X defends delay

Brazil's Ministry of Health will require insulin suppliers to have Anvisa registration in a new tender, excluding unregistered companies from the SUS market. Global X defends the wait for Anvisa, citing regulatory compliance. This could limit competition and affect insulin supply to the public health system.